NASDAQ:CAMP CAMP4 Therapeutics (CAMP) Stock Price, News & Analysis $4.24 +0.21 (+5.21%) Closing price 04:00 PM EasternExtended Trading$4.24 +0.00 (+0.12%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About CAMP4 Therapeutics Stock (NASDAQ:CAMP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CAMP4 Therapeutics alerts:Sign Up Key Stats Today's Range$3.95▼$4.2750-Day Range$3.01▼$5.4452-Week Range$2.20▼$7.75Volume1.04 million shsAverage Volume251,857 shsMarket Capitalization$266.06 millionP/E RatioN/ADividend YieldN/APrice Target$9.79Consensus RatingModerate Buy Company Overview CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company developing RNA-based medicines for genetic diseases caused by insufficient expression of essential proteins. The company’s approach is designed to increase the body’s production of naturally occurring proteins by activating the transcription of specific genes, potentially addressing the underlying cause of disease rather than only treating symptoms. CAMP4’s technology platform uses RNA-based gene-activation therapeutics intended to target regulatory regions associated with disease-relevant genes. Its development programs are focused on conditions in which restoring or increasing expression of a functional gene product may provide a therapeutic benefit. The company’s lead program, CMP-CPS-001, is being developed for carbamoyl phosphate synthetase 1 deficiency, a rare inherited disorder that affects the urea cycle and can cause the accumulation of toxic ammonia in the blood. Based in Cambridge, Massachusetts, CAMP4 Therapeutics was established to advance programmable gene-control medicines for rare and other genetically driven diseases. The company is conducting preclinical and clinical development activities and has focused its initial efforts on rare disorders with significant unmet medical needs. Additional information about its broader pipeline and leadership is limited relative to more established biopharmaceutical companies.AI Generated. May Contain Errors. Read More CAMP4 Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreCAMP MarketRank™: CAMP4 Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 273rd out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingCAMP4 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCAMP4 Therapeutics has a consensus price target of $9.79, representing about 130.8% upside from its current price of $4.24.Amount of Analyst CoverageCAMP4 Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about CAMP4 Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for CAMP4 Therapeutics are expected to decrease in the coming year, from ($0.57) to ($0.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CAMP4 Therapeutics is -1.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CAMP4 Therapeutics is -1.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCAMP4 Therapeutics has a P/B Ratio of 4.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.41% of the float of CAMP4 Therapeutics has been sold short.Short Interest Ratio / Days to CoverCAMP4 Therapeutics has a short interest ratio ("days to cover") of 4.16.Change versus previous monthShort interest in CAMP4 Therapeutics has recently decreased by 7.04%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCAMP4 Therapeutics does not currently pay a dividend.Dividend GrowthCAMP4 Therapeutics does not have a long track record of dividend growth. News and Social Media1.7 / 5News SentimentN/A News SentimentCAMP4 Therapeutics has a news sentiment score of 0.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies. Company Ownership2.9 / 5Insider TradingSelling Shares Cluster Insider Buying4 insiders have purchased shares of CAMP4 Therapeutics in the last three months. Multiple insiders buying is a strong bullish signal.Insider Buying vs. Insider SellingIn the past three months, CAMP4 Therapeutics insiders have sold 2,428.03% more of their company's stock than they have bought. Specifically, they have bought $99,051.00 in company stock and sold $2,504,037.00 in company stock.Percentage Held by Insiders21.69% of the stock of CAMP4 Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsCAMP4 Therapeutics has minimal institutional ownership at this time.Read more about CAMP4 Therapeutics' insider trading history. Receive CAMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CAMP4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CAMP Stock News HeadlinesCAMP4 Therapeutics Secures UK Authorization For CMP-002 Clinical Trial In SYNGAP1 DisorderSeptember 10, 2026 | rttnews.comCAMP4 Therapeutics Gets Clearance to Conduct Phase 1/2 Study for SYNGAP1-Related Disorder Treatment in UKSeptember 10, 2026 | finance.yahoo.comIran War: Why Is Trump Protecting THEM?A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military protection against Iran-backed forces. An anonymous source says that protection was only one side of an extraordinary bargain, with the other side potentially worth trillions of dollars to America. Addison Wiggin traced the deal linking Trump, Iran, and this government, and says the headlines look very different once you know who is involved.September 18 at 1:00 AM | Banyan Hill Publishing (Ad)CAMP4 Therapeutics Receives MHRA Authorization to Include UK Sites in Global Phase 1/2 Trial of CMP-002 for SYNGAP1-Related DisorderSeptember 10, 2026 | quiverquant.comQCAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related DisorderSeptember 10, 2026 | globenewswire.comInsider Buying: CAMP4 Therapeutics (NASDAQ:CAMP) CFO Acquires 10,000 Shares of StockSeptember 3, 2026 | insidertrades.comInsider Selling: CAMP4 Therapeutics (NASDAQ:CAMP) Director Sells $1,616,000.00 in StockSeptember 1, 2026 | insidertrades.comCAMP4 Therapeutics (NASDAQ:CAMP) Director Andrew Schwab Sells 32,018 SharesAugust 22, 2026 | insidertrades.comSee More Headlines CAMP Stock Analysis - Frequently Asked Questions How have CAMP shares performed this year? CAMP4 Therapeutics' stock was trading at $6.0850 at the beginning of 2026. Since then, CAMP stock has decreased by 30.3% and is now trading at $4.24. How were CAMP4 Therapeutics' earnings last quarter? CAMP4 Therapeutics Corporation (NASDAQ:CAMP) released its quarterly earnings results on Thursday, August, 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.34. The Wireless communications provider had revenue of $1.78 million for the quarter. CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative trailing twelve-month return on equity of 252.79%. When did CAMP4 Therapeutics' stock split? Shares of CAMP4 Therapeutics reverse split on the morning of Friday, February 2nd 2024.The 1-23 reverse split was announced on Friday, February 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Does CAMP4 Therapeutics have any subsidiaries? The following companies are subsidiaries of CAMP4 Therapeutics: LoJack, Gulfstream Telematics, SmartLink Radio Networks, CalAmp Wireless Networks Inc., Skybility, Boisen S.A., CalAmp Importation and Leasing of Tracking Equipment Ltd., and more. When did CAMP4 Therapeutics IPO? CAMP4 Therapeutics (CAMP) raised $102 million in an initial public offering (IPO) on Friday, October 11th 2024. The company issued 6,820,000 shares at $14.00-$16.00 per share. Who are CAMP4 Therapeutics' major shareholders? CAMP4 Therapeutics' top institutional investors include Jupiter Topco LLC (10.05%), 5AM Venture Management LLC (9.35%), Trails Edge Capital Partners LP (3.08%) and BlackRock Inc. (3.17%). Insiders that own company stock include 5Am Partners Vi, Llc, Amir Nashat, Polaris Management Co Vii, L, Andrew J Schwab, Josh Mandel-Brehm, Richard A Young, Yuri Maricich, Kelly Gold, Jason Cohenour and Daniel Tardiff. View institutional ownership trends. How do I buy shares of CAMP4 Therapeutics? Shares of CAMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CAMP4 Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CAMP4 Therapeutics investors own include Zimmer Biomet (ZBH), Union Pacific (UNP), Charter Communications (CHTR), NVIDIA (NVDA), PayPal (PYPL), MercadoLibre (MELI) and Meta Platforms (META). Company Calendar Last Earnings8/13/2026Today9/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 CAMP's financial health is in the Green zone, according to TradeSmith. CAMP has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CAMP CIK730255 Webwww.calamp.com Phone(949) 600-5600Fax805-856-3857Employees644Year Founded1981Price Target and Rating Average Price Target for CAMP4 Therapeutics$9.79 High Price Target$15.00 Low Price Target$6.50 Potential Upside/Downside+130.8%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($2.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$80.40 million Net Margins-2,543.74% Pretax Margin-2,543.74% Return on Equity-252.79% Return on Assets-85.65% Debt Debt-to-Equity RatioN/A Current Ratio4.70 Quick Ratio4.70 Sales & Book Value Annual Sales$3.50 million Price / Sales76.02 Cash FlowN/A Price / Cash FlowN/A Book Value$1.02 per share Price / Book4.16Miscellaneous Outstanding Shares62,750,000Free Float49,142,000Market Cap$266.06 million OptionableNo Data Beta0.27 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:CAMP) was last updated on 9/18/2026 by MarketBeat.com Staff. From Our Partners$40,000,000,000,000The national debt just hit 40 trillion dollars, and the U.S. now spends more on interest payments than on its ...American Alternative | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredIran War WARNING: Something Just ChangedA powerful Middle Eastern government is reportedly asking Trump for U.S. military help against Iran backed for...Banyan Hill Publishing | SponsoredWhy I went to Mount RushmoreA small miner just hit on gold in the hills surrounding Mount Rushmore, thanks to a breakthrough new technolog...Stansberry Research | SponsoredMy next big call (under $1)17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CAMP4 Therapeutics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share CAMP4 Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
